Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy A Turning Point for Peptides? What RFK Jr.'s Announcement Could Mean for the Future of Wellness and Longevity Skytale Group The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Updated 2026 FDA Category 2 peptide list As the science and regulations continue to develop, it's important to work with providers who stay informed and prioritize safe, medically guided protocols. At